CYTOMETRY AND ANTIBODY TECHNOLOGY

细胞计数和抗体技术

• 批准号: 8486626
• 负责人: MICHELLE M LE BEAU
• 金额: $ 12.84万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8486626
• 关键词: Advisory Committees; Antibodies; Area; Basic Science; Cancer Center; Cancer Center Support Grant; Cell Separation; Cells; Chicago; Classification; Client; Clinical Research; Comprehensive Cancer Center; Consultations; Continuing Education; Core Facility; Coupled; Cytometry; Detection; Diagnosis; Disease; Educational workshop; Faculty; Flow Cytometry; Fluorescence; Future; Goals; Home environment; Human Resources; Hybridomas; Image; Image Cytometry; Instruction; Label; Lasers; Malignant Neoplasms; Measurement; Measures; Mission; Monoclonal Antibodies; Phenotype; Production; Property; Proteins; Reagent; Research; Research Personnel; Research Project Grants; Resources; Role; Services; Speed; Strategic Planning; Techniques; Technology; Training; Translational Research; Universities; Update; Work; antibody conjugate; anticancer research; base; cancer prevention; cancer therapy; design; detector; improved; instrumentation; interdisciplinary approach; leukemia/lymphoma; meetings; member; monoclonal antibody production; novel; operation; protocol development; quality assurance; research facility; tool

PROJECT SUMMARY (See instructions): The Cytometry and Antibody Technology (CAT) Facility serves the University of Chicago Comprehensive Cancer Center (UCCCC) membership by providing all of the tools necessary to measure properties of cells and their products. The Fitch Monoclonal Subcore (FMS) develops the reagents used to label the cells, whereas the Flow Cytometry Subcore (FCS) provides the technology and staff expertise to use these reagents for experimental measurements. During the past 35 years, antibodies have become reliable and necessary tools in the continuously growing interdisciplinary approach to basic and clinical research, as well as the diagnosis, and treatment of disease. Antibody technology and its usage have evolved concurrently with flow and image cytometry and has become the dominant tool for the identification and classification of cells and cellular products, especially in the areas of cancer research. The Facility is utilized by UCCCC investigators in many areas of study involved in the basic and translational research of cellular phenotype and function. The specific aim of the CAT Facility is to provide instrumentation and antibodies for the analytical detection of subcellular components and proteins using a range of fluorescence and non-fluorescence-based detection technologies. Further, the CAT Facility is designed to meet the wide-spread needs for specialized cytometric analysis and continues to respond to the demand for new and improved technology. Among these improvements include an expanding Antibody/Hybridoma Bank that provides commonly used, highest quality purified antibodies, pre-titered conjugated antibodies for flow cytometry, and hybridoma lines to UCCCC investigators. Cytometric technology improvements include the latest in high-speed cell sorting, multi-laser analyzers for performing polychromatic flow cytometry. Image-based cytometers, and bead-based analyte detectors.

项目摘要(见说明)：细胞学和抗体技术(CAT)设施为芝加哥大学综合癌症中心(UCCCC)成员提供测量细胞及其产品特性所需的所有工具。惠誉单抗亚核(FMS)开发用于标记细胞的试剂，而流式细胞术亚核(FCS)提供使用这些试剂进行实验测量的技术和工作人员专业知识。在过去的35年里，抗体已经成为基础和临床研究以及疾病诊断和治疗的持续增长的跨学科方法中可靠和必要的工具。抗体技术及其使用与流式细胞术和图像细胞术同时发展，并已成为细胞和细胞产品鉴定和分类的主导工具，特别是在癌症研究领域。该设备被UCCCC的研究人员用于许多研究领域，涉及细胞表型和功能的基础和翻译研究。CAT设施的具体目标是使用一系列基于荧光和非荧光的检测技术，为亚细胞成分和蛋白质的分析检测提供仪器和抗体。此外，CAT设施旨在满足专业细胞分析的广泛需求，并继续响应对新的和改进的技术的需求。这些改进包括扩大抗体/杂交瘤银行，为UCCCC调查人员提供常用的、最高质量的纯化抗体、用于流式细胞术的预滴定结合抗体和杂交瘤株。细胞学技术的改进包括最新的高速细胞分选，用于执行多色流式细胞术的多激光分析仪。基于图像的细胞仪和基于珠粒的分析物检测器。